3.40Open3.40Pre Close0 Volume53 Open Interest10.00Strike Price0.00Turnover135.00%IV10.57%PremiumJan 17, 2025Expiry Date2.62Intrinsic Value100Multiplier23DDays to Expiry0.78Extrinsic Value100Contract SizeAmericanOptions Type-0.7617Delta0.1239Gamma2.54Leverage Ratio-0.0158Theta-0.0044Rho-1.94Eff Leverage0.0058Vega
Vir Biotechnology Stock Discussion
US FDA: Revoked Emergency Use Authorization for GSK and Vir Biotechnology's Sotrovimab as of Dec 13 - Website
*************************************
REVERSE...
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
📊⚡️📊
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
📊⚡️📊
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Phase 3 Eclipse Program to Evaluate Tobevibart and Elebsiran
No comment yet